After The Supply Pact, Will GSK Go For An Equity Deal With Dr. Reddy's?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Weeks after the Paris-headquartered Sanofi-Aventis acquired Hyderabad-based Shantha Biotechnics to galvanize the French drug maker's preventative vaccines manufacturing, analysts are now predicting a deal between Britain's GlaxoSmithKline and Dr. Reddy's - India's second biggest pharmaceutical company as measured by sales
You may also be interested in...
M&A In India May Lose Steam As Potential Sellers Raise Prices, Investment Bankers Say
A rebound in the Indian stock market and two recent high-value takeovers sparked "irrational hope" in overvalued mid-size companies.
M&A In India May Lose Steam As Potential Sellers Raise Prices, Investment Bankers Say
A rebound in the Indian stock market and two recent high-value takeovers sparked "irrational hope" in overvalued mid-size companies.
M&A In India May Lose Steam As Potential Sellers Raise Their Price Tags, Investment Bankers Say
MUMBAI - Greed is getting in the way of several prospective mergers and acquisitions in the Indian pharmaceutical industry, two senior investment bankers told PharmAsia News, but reiterated that multinational companies are still keenly scanning companies that fit into their global programs